The Role of PET-Based Radiomic Features in Predicting Local Control of Esophageal Cancer Treated with Concurrent Chemoradiotherapy

• Published in: Scientific reports 2018-07, Vol.8 (1), p.9902-11, Article 9902
• Main Authors: Xiong, Junfeng, Yu, Wen, Ma, Jingchen, Ren, Yacheng, Fu, Xiaolong, Zhao, Jun
• Format: Article
• Language: English
• Subjects: 59/78; 639/166/985; 692/4028/67/2321; Cancer; Chemoradiotherapy; Chemotherapy; Esophageal cancer; Esophagus; Health risk assessment; Humanities and Social Sciences; Learning algorithms; multidisciplinary; Patients; Positron emission tomography; Radiation therapy; Radiomics; Risk factors; Risk groups; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-28243-x

This study was designed to evaluate the predictive performance of 18 F-fluorodeoxyglucose positron emission tomography (PET)-based radiomic features for local control of esophageal cancer treated with concurrent chemoradiotherapy (CRT). For each of the 30 patients enrolled, 440 radiomic features were extracted from both pre-CRT and mid-CRT PET images. The top 25 features with the highest areas under the receiver operating characteristic curve for identifying local control status were selected as discriminative features. Four machine-learning methods, random forest (RF), support vector machine, logistic regression, and extreme learning machine, were used to build predictive models with clinical features, radiomic features or a combination of both. An RF model incorporating both clinical and radiomic features achieved the best predictive performance, with an accuracy of 93.3%, a specificity of 95.7%, and a sensitivity of 85.7%. Based on risk scores of local failure predicted by this model, the 2-year local control rate and PFS rate were 100.0% (95% CI 100.0–100.0%) and 52.2% (31.8–72.6%) in the low-risk group and 14.3% (0.0–40.2%) and 0.0% (0.0–40.2%) in the high-risk group, respectively. This model may have the potential to stratify patients with different risks of local failure after CRT for esophageal cancer, which may facilitate the delivery of personalized treatment.